Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. held its 2026 annual meeting of stockholders on July 13, 2026. Stockholders elected seven directors to serve until the 2027 annual meeting and ratified the appointment of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for fiscal year 2026. Following the meeting, the Board of Directors appointed members to its Audit, Compensation, and Nominating and Governance Committees.

Canton Strategic Holdings, Inc. announced its 2026 Annual Meeting of Stockholders will take place virtually on July 13, 2026. Shareholders will vote on the election of seven directors and the ratification of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board of Directors recommends voting for all proposals, including the election of new nominees Sean Galvin, Pamela L. Carter, and Rishi Nangalia, as three current directors are not standing for re-election.

Canton Strategic Holdings, Inc. announced that its Board of Directors authorized a share repurchase program for up to $50 million of its outstanding common stock. The program allows for repurchases through open market transactions, privately-negotiated deals, or Rule 10b-18 trading plans. The company has engaged Virtu Americas LLC as a non-exclusive agent for repurchases under a Rule 10b-18 plan, paying a commission of $0.02 per share. The program is flexible and does not obligate the company to repurchase shares.

Canton Strategic Holdings reported a net loss of $(47.3) million for Q1 2026, significantly wider than the $(2.5) million loss in Q1 2025, primarily due to increased general and administrative expenses and a $(15.0) million unrealized loss from digital asset holdings. The company continued its digital asset treasury strategy, increasing its Canton Coin holdings to $541.6 million. Financing activities provided $87.0 million in cash, largely from equity offerings, supporting a substantial increase in cash reserves to $41.5 million. Additionally, its biotech subsidiary, Gravitas, received positive FDA feedback for its GV104 development candidate.